Clearmind Medicine is expanding beyond its psychedelic therapeutics by purchasing a 51% stake in Charging Robotics for $2.5 million, plus a $1.5 million loan at 4% due three years after closing with automatic extension if cash flow falls short. The deal targets up to 10 kW wireless charging for autonomous platforms and robotaxis, but investors pushed CMND shares lower ahead of a Sept. 7 closing date, signaling concern over execution risk and valuation impact.
Clearmind Medicine announced that its independent DSMB unanimously approved moving CMND-100 into Parts B and C of the Phase I/II trial for alcohol use disorder, following Part A's favorable safety data. Part B tests 80 mg and 160 mg in AUD patients, while Part C evaluates a 160 mg daily dose in healthy participants, aiming to better characterize safety and early activity signals.
Clearmind Medicine Inc. announced that its CMND-100 drug candidate met primary safety endpoints in a Phase I/IIa trial for Alcohol Use Disorder. The positive results bolster confidence in advancing CMND-100 as a potential treatment, enhancing the company's position in the growing psychedelic therapeutics market.
